Patents by Inventor Girija Krishnamurthy

Girija Krishnamurthy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7867699
    Abstract: The invention relates to a novel method of inexpensively synthesizing large quantities of an essentially pure, biologically active, glycosylated Dkk protein, including mammalian and human Dkk proteins (e.g., human Dkk1). The invention further relates to the synthetically produced essentially purified, glycosylated and biologically active Dkk protein, and the characteristics of the protein.
    Type: Grant
    Filed: March 23, 2005
    Date of Patent: January 11, 2011
    Assignees: Wyeth, Oscient Pharmaceuticals Corporation
    Inventors: Kristina Allen, Anthony Anisowicz, Wei Chen, Girija Krishnamurthy, Matthew Olson
  • Publication number: 20080279874
    Abstract: Described are compositions and methods for activating a Plk1 protein as well as phospho-specific anti-Myt1 antibodies that can be used to detect phosphorylation of Myt1. Activated Plk1 protein, phospho-specific anti-Myt1 antibodies, and/or Plk1 substrates can be used in screening assays to identify compounds that modulate the ability of Plk1 to phosphorylate and/or bind to a Plk1 substrate.
    Type: Application
    Filed: May 6, 2008
    Publication date: November 13, 2008
    Applicant: Wyeth
    Inventors: Frank Loganzo, JR., Girija Krishnamurthy, Weidong Warren Ding, Xingzhi Cindy Tan, Jagruti Hasmukh Patel
  • Publication number: 20080038775
    Abstract: The invention relates to a novel method of inexpensively synthesizing large quantities of an essentially pure, biologically active, glycosylated Dkk protein, including mammalian and human Dkk proteins (e.g., human Dkk1). The invention further relates to the synthetically produced essentially purified, glycosylated and biologically active Dkk protein, and the characteristics of the protein.
    Type: Application
    Filed: March 23, 2005
    Publication date: February 14, 2008
    Applicants: WYETH, OSCIENT PHARMACEUTICALS CORPORATION
    Inventors: Kristina Allen, Anthony Anisowicz, Wei Chen, Girija Krishnamurthy, Matthew Olson
  • Publication number: 20060276464
    Abstract: Compounds of Formula 1, or pharmaceutically acceptable salts thereof, are provided: which are modulators of secreted frizzled related protein-1. The compounds, and compositions containing the compounds, can be used to treat a variety of disorders, including osteoporosis.
    Type: Application
    Filed: May 10, 2006
    Publication date: December 7, 2006
    Applicant: Wyeth
    Inventors: Ariamala Gopalsamy, William Moore, Jeffery Kern, Albert Molinari, Mengxiao Shi, Gregory Welmaker, Mathew Wilson, Girija Krishnamurthy, Thomas Commons, Michael Webb, Richard Woodworth
  • Patent number: 6399314
    Abstract: A method/assay for detecting various aggregated forms of amyloid peptide using amyloid-specific spectroscopic probes, such as Congo red and related analogs, is described. Such an assay could be used to assess the aggregation state of the peptide in the presence of other potential inhibitors of fibrillogenesis, providing a useful model by which to test inhibitors of aggregation in in vitro models. Results of such an assay can be useful in determining the stage at which the process of aggregation can be intervened to reduce the toxicity of amyloid peptide to neuronal cells. In specific examples, circular dichroism, UV absorption, and fluorescence spectroscopy are each used to evaluate the aggregation form of &bgr;-amyloid peptide.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: June 4, 2002
    Assignee: American Cyanamid Company
    Inventor: Girija Krishnamurthy